The August edition of our People Pathways newsletter is out now! Read the newsletter here.You can read about:✅ One Nucleus upcoming courses - don't forget, as a One Nucleus member, you can access discounts up to 30%;✅ Our upcoming BLSA SIG webinar on the Green Business Impact Programme jointly delivered by Allia and PECT;✅ EBD Academy courses - member savings available;and more...
WEST CHESTER, Pa. and CAMBRIDGE, England – Wednesday, August 21, 2024 – Supreme Group today announced the acquisition of BioStrata, an award-winning agency offering comprehensive marketing communication services to the life science sector. Based in Cambridge, UK, and servicing clients globally, BioStrata has helped more than 200 life science organizations achieve their business goals across life science research tools, medical devices, diagnostics, contract research and manufacturing, biopharma, and other areas.
This strategic addition, backed by growth-oriented private equity firm…
The MycoScope™ Mycoplasma PCR detection kit from AMSBIO uses polymerase chain reaction (PCR) technology to detect mycoplasma infections in less than 3 hours. Offering high-sensitivity detection, rapid results, and compatibility with existing PCR setups, this kit reduces the risk of contamination spread saving valuable time and resources.
As reported in the ISSCR standards report (2023) a sizeable proportion of cell cultures (up to >80%) are infected with mycoplasma. While contaminating mycoplasma may grow slowly without killing the cells, the infection affects…
The biopharma industry veteran, founder of Medivation, and serial entrepreneur joins T-Therapeutics to support the development of the biotechnology company’s pipeline of next-generation soluble TCR therapeutics targeting cancer and autoimmune indications.
Dr. Hung is a successful serial entrepreneur in the oncology space. He founded Medivation in 2003 which was sold to Pfizer for $14.3 billion in 2016. At Medivation, Dr. Hung identified, in-licensed, and led bench-to-bedside development of enzalutamide (XTANDI®) for advanced prostate cancer, taking it from first in vitro laboratory experiment…
Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed Carlos Garcia-Echeverria, Katharina Kreymborg and Karen Lackey as the first members of its Therapeutic Innovation board to steer its drug discovery strategy.
Therapeutic Innovation is Cancer Research Horizons’ drug discovery division. From target identification to candidate drug nomination, Therapeutic Innovation’s scientists collaborate with academic and industrial partners to progress promising ideas, de-risk assets and bring projects to their next value inflection point.
The new board members’ experience…
This article will explore two commonly used sequencing methods, NGS vs Sanger Sequencing sequencing methods, looking at how they work, their respective advantages and disadvantages, and their applications.
Read our latest blog here:
https://sourcebioscience.com/ngs-v-sanger-sequencing/
Baseimmune facilitates growth with move to the Apex Building, part of the Tribeca development - London’s latest grow-on lab space
Latest sign-up increases LBIC’s pre-let occupancy at Apex to 35%
LONDON, UK 19th August 2024: London BioScience Innovation Centre (LBIC) is delighted to announce that it has entered into an Agreement for Lease with Baseimmune Ltd. The novel vaccine developer will occupy 3,350 sq ft of lab and office space in LBIC’s new, fully fitted, grow-on space within the Apex building, located in the heart of the King’s Cross Knowledge Quarter. This increases pre-…
Cellomatics Biosciences, a Nottingham-based preclinical contract research organisation, continues to expand its global client base by adding two new members of staff to support its business development efforts.
The company has welcomed Dr Pier Giorgio Amendola and Dr Jyoti Mundra to assist the company with its expansion into both European and US markets.
A key challenge for UK-based CROs operating internationally is managing cultural differences and regional market dynamics. Pier will use his experience to navigate these challenges in European markets and build strong local partnerships. He…
Three innovative R&D companies have expanded into the state-of-the-art Hexagon Tower in Blackley, signalling a growing interest in science infrastructure outside of Manchester city centre, according to site operator Pioneer Group.
Hexagon Tower, part of Pioneer Group’s wider life sciences network that includes 645 R&D businesses across Europe, is a significant R&D landmark in Manchester, located next to North Manchester General Hospital (NMGH).
Designed by the renowned modernist architect Richard Seifert, the 11 floor, 165,000 sq ft building opened in 1973 and has become one of…